Skip to content

Pilot Study Evaluating the Impact of Stress Reduction on Atherosclerotic : Heart and Mind Study

Pilot Study Evaluating the Impact of Stress Reduction on Atherosclerotic : Heart and Mind Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04496947
Enrollment
30
Registered
2020-08-04
Start date
2018-09-01
Completion date
2027-12-31
Last updated
2026-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Inflammation, Stress

Brief summary

The plot study aims to evaluate the effect of 8 weeks of stress reducing intervention on atherosclerotic plaque inflammation in adults, as quantified by positron emission tomography (PET) with fluorine-2-deoxy-D-glucose (FDG) in individuals with increased psychosocial stress.

Detailed description

This randomized controlled imaging study will be performed to evaluate the impact of mindfulness-based stress reduction via a mind body program on arterial inflammation in individuals with self-identified high levels of stress. Individuals will undergo baseline Fluorodeoxyglucose-Positron emission tomography / magnetic resonance imaging and will then be randomized to the stress-reduction intervention group or no intervention groups by blocks of 2:1, with stratification by age and sex. The stress reduction sessions focus on developing an understanding of stress physiology and the physiology of the relaxation response, on developing a regular practice of eliciting the relaxation response, and on learning cognitive behavioral and positive psychology/resilience skills. During the screening period, patient acceptability for the study will be assessed based on medical history, concomitant medications, physical examination, and clinical laboratory test results. Acceptability for study participation will be confirmed for subjects who identify as having increased levels of stress and/or a Perceived Stress Scale score \>5. Once the patient has passed screening, they will undergo baseline imaging followed by randomization and group assignment. Approximately 12 weeks after randomization, all individuals will return for follow-up imaging and evaluation. Thus, 2 Fluorodeoxyglucose-Positron emission tomography / magnetic resonance imaging scans will be performed throughout the study for baseline and follow up to assess the intervention's impact on the brain and arterial inflammation, along with changes in related positron emission tomography / magnetic resonance imaging imaging parameters. Perceived Stress Scale will be delivered prior to Fluorodeoxyglucose-Positron emission tomography / magnetic resonance imaging, during both imaging visits to measure perceived psychological stress. During both imaging sessions, subjects will be exposed to overt faces to measure signals during brain imaging.

Interventions

BEHAVIORALStress Reduction

The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session: * Elicitation of the Relaxation Response (RR) through mind-body techniques; * Discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and * Coping strategies and adaptive perspective-taking to promote positive well-being.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Intervention model description

2 groups: 1. stress reduction intervention 2. no intervention

Eligibility

Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* • Aged between 30-65 years * Identifies as having increased levels of stress and/or has a Perceived Stress Scale (PSS) score \>5 at baseline, and is interested in participating

Exclusion criteria

* Perceived Stress Scale (PSS) score \<6

Design outcomes

Primary

MeasureTime frameDescription
Change in arterial inflammation by PET2 monthsChange in arterial inflammation based on FDG PET - from initial imaging to repeat imaging.

Countries

United States

Contacts

CONTACTAhmed Tawakol, MD
atawakol@mgh.harvard.edu6177243699
PRINCIPAL_INVESTIGATORAhmed Tawakol, MD

MGH

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 4, 2026